Evidence map›Paper›PMID 42030265›Full record

Trial reportCancer medicine2026

Mecapegfilgrastim for Prophylaxis of Immunochemotherapy-Induced Neutropenia in Patients With Diffuse Large B-Cell Lymphoma: A Multicenter Pilot Trial.

Jie Wang, He Li, Qiaochu Lin, Yong Guo, Hongbing Ma, Bing Xiang, Chenlu Yang, Kai Shen, Chunlan Zhang, Kun Yang and 6 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jie WangDepartment of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
He LiDepartment of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Qiaochu LinDepartment of Hematology, West China Xiamen Hospital of Sichuan University, Xiamen, Fujian Province, China.
Yong GuoDepartment of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.ORCID https://orcid.org/0000-0002-4103-6304
Hongbing MaDepartment of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.ORCID https://orcid.org/0000-0002-1174-4078
Bing XiangDepartment of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.ORCID https://orcid.org/0000-0002-3069-2787
Chenlu YangDepartment of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Kai ShenDepartment of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.ORCID https://orcid.org/0000-0002-7772-8011
Chunlan ZhangDepartment of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.ORCID https://orcid.org/0000-0003-4226-7451
Kun YangDepartment of Hematology, Nanchong Central Hospital, Nanchong, Sichuan Province, China.
Chunrong MaDepartment of Hematology, Nanchong Central Hospital, Nanchong, Sichuan Province, China.
Hong ZhaiDepartment of Hematology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, China.
Jin WeiDepartment of Hematology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, China.
Yan ZuoDepartment of Hematology, Deyang People's Hospital, Deyang, Sichuan Province, China.
Jie ZhouDepartment of Hematology, Deyang People's Hospital, Deyang, Sichuan Province, China.
Ting NiuDepartment of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.ORCID https://orcid.org/0000-0003-1580-1014

Funding

1.3.5 Project of Center for High Altitude Medicine, West China Hospital, Sichuan University GYYX24003National Natural Science Foundation of China 82370192National Natural Science Foundation of China U24A20680
6 · The paper itself

Abstract

backgroundThis study evaluated the efficacy and safety of mecapegfilgrastim for preventing immunochemotherapy-induced neutropenia in treatment-naive patients with diffuse large B-cell lymphoma (DLBCL).

methodsIn this open-label, multicenter exploratory trial, patients were randomized in a 2:1 ratio to receive mecapegfilgrastim or no prophylaxis. All participants received 4 cycles of R-CHOP or R-CHOP-like regimens. The primary endpoint was the incidence of grade ≥ 3 neutropenia during cycle 1.

resultsBetween October 2021 and June 2024, 42 patients were enrolled (mecapegfilgrastim: n = 28; control: n = 14). Grade ≥ 3 neutropenia in cycle 1 occurred in 32.14% of the mecapegfilgrastim group versus 64.29% in the control group. Across all cycles, mecapegfilgrastim consistently reduced grade ≥ 3 neutropenia; nadir neutrophil counts were higher and the need for short-acting granulocyte colony-stimulating factor was lower in the mecapegfilgrastim group (all nominal p ≤ 0.05). No cases of febrile neutropenia occurred in the mecapegfilgrastim group, compared to one case in the control group. Objective response rates were 75.0% (95% CI: 55.1, 89.3) and 57.1% (95% CI: 28.9, 82.3), respectively (nominal p = 0.298). Mecapegfilgrastim reduced the incidence of grade ≥ 3 neutropenia regardless of treatment response. Grade ≥ 3 treatment-emergent adverse events (TEAEs) occurred in 42.9% of the mecapegfilgrastim group and 92.9% of controls; serious TEAEs were reported in 7.1% of patients in both groups.

conclusionsMecapegfilgrastim demonstrated a favorable safety profile and potential efficacy in reducing the incidence and severity of neutropenia in DLBCL patients receiving R-CHOP or R-CHOP-like regimens. These findings may support its prophylactic use in this population and warrant validation in larger trials.

trial registrationchictr.org.cn: ChiCTR2100048196. Registered on July 4, 2021.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsFilgrastimLymphoma, Large B-Cell, DiffuseNeutropeniaAdultAgedCyclophosphamideDoxorubicinFemaleHumansMaleMiddle AgedPilot ProjectsPrednisoneRituximabVincristineCyclophosphamideDoxorubicinFilgrastimPrednisoneR-CHOP protocolRituximabVincristineDLBCLhematologic malignanciesimmunochemotherapylong‐acting G‐CSFneutropeniaPEG‐rhG‐CSF

Identifiers

PMID42030265
PMCPMC13108669

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.